Skip to main content
. 2013 Jun 4;4(5):772–784. doi: 10.18632/oncotarget.1028

Figure 1. 3-D Waterfall plot.

Figure 1

Best response by RECIST, of 15 NSCLC patients with EGFR positive-mutations treated with an EGFR inhibitor-based regimen. Patients with clinical progression or with new metastases were graphed as 20% progression. Time to treatment failure in months is represented by solid lines and the arrow indicates that the patient was still on study when the data was censored. Patients with PIK3CA mutations in addition to EGFR mutation and patients who received prior EGFR inhibitor therapy are designated as such. Dotted horizontal line at -30% indicates border for partial response.